The Genetic Polymorphisms of CYP3A4*1G and CYP3A5*3 in Javanese Indonesian Population

by FEB UBHARA

Research Article

The Genetic Polymorphisms of *CYP3A4*1G* and *CYP3A5*3* in Javanese Indonesian Population

Sarah Puspita Atmaja [1]*, Ellsya Angeline Rawar [1], Ani Kristiyani [1], Dwi Aris Agung Nugrahaningsih [2], Ahmad Hamim Sadewa [3], Christine Patramurti [4]

[1] Faculty of Pharmacy, Universitas Kristen Immanuel, Sleman 55571, Indonesia
[2] Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia
[3] Department of Biochemistry, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia
[4] Faculty of Pharmacy, Sanata Dharma University, Yogyakarta 55282, Indonesia

ABSTRACT

Polymorphisms of *CYP3A4*1G* and *CYP3A5*3* affect the pharmacokinetic profile of various drugs, e.g., fentanyl, tacrolimus, diltiazem, simvastatin. Tetra-primer amplification refractory mutation system-polymerase chain (ARMS-PCR) is a simple and economical method for SNP determination. The polymorphisms in the *CYP3A4*1G* and *CYP3A5*3* genes have not yet been examined using this method in Javanese Indonesian. Our aim was to determine the frequency of polymorphisms in the *CYP3A4*1G* and *CYP3A5*3* genes in Indonesian Javanese using the ARMS-PCR method. Eighty-six patients at the Kalasan Community Health Centre in Yogyakarta, Indonesia, were chosen based on the inclusion criteria, which is Javanese ancestry. They gave their informed consent to blood collection by completing a form. Genetic variants were detected using Tetra-primer amplification refractory mutation system-polymerase chain (ARMS-PCR). The chi-square test was used to determine genotype deviations from Hardy-Weinberg equilibrium, with a significant threshold of 0.05. For homozygous wild types, *CYP3A4 *1/*1* dominated overall among study participants (73.35%), whereas for *CYP3A5*3/*3*, homozygous mutants were more prevalent (83.72%). Hardy-Weinberg equilibrium is consistent with genotype frequencies (p > 0.005). One participant carried a homozygous mutation for both *CYP3A4*1G* and *CYP3A5*3*, while the other 49 subjects were heterozygous for *CYP3A4*1G* and homozygous mutant for *CYP3A5*3*, which is the highest number of SNP combinations. The findings of the current investigation demonstrate that the population has the highest proportion of homozygous *CYP3A4*1G* wild-types (*CYP3A4*1/*1*) and homozygous mutants for *CYP3A5*3* (*CYP3A5*3/*3*)

Keywords: ARMS-PCR, *CYP3A4*1G*, *CYP3A5*3*, Indonesian, Javanese, Polymorphism

Introduction

Gene variations in the human body are responsible for drug efficacy and safety changes. The CYP3A4 and CYP3A5 genes are two genes responsible for encoding cytochromes that metabolize endogenous and exogenous substances. These genes belong to the cytochrome P450 genes located on chromosome 7q22.1 [1]. The two genes have similar structures that produce overlapping substrates [2].

There are 139 known variants of the CYP3A4 single nucleotide polymorphism (SNP). The wild type of *CYP3A4* is *CYP3A4*1A*, while *CYP3A4*1B* is a -392A>G mutation in the 5'UTR region. Another variant is *CYP3A4*1G*, located in

intron 10 of the CYP3A4 gene and mostly found in Asian populations [3]. The CYP3A5 gene has 25 allelic variants, and the most common allele found in the population is *CYP3A5*3* [4].

Individuals with *CYP3A4*1G* showed variations in the pharmacokinetic profiles of fentanyl, tacrolimus, diltiazem, sufentanil, and tylerdipine hydrochloride [5-9]. An increased risk of breast cancer occurrence is known to be associated with *CYP3A4*1G* polymorphism [10]. Individuals carrying *CYP3A5*3/*3* have increased simvastatin levels, while studies on tacrolimus therapy found that individuals with *CYP35 *1/*1* and **1/*3* variants take longer to reach steady-state levels than those with *CYP3A5*3/*3* [11],[12].

SNP detection methods using sequencing have many advantages, namely precision and reliability, but also limitations, namely high prices. The RFLP method also has an expensive price and can lead to incomplete and/or partial digestion, resulting in false negatives or positives [13]. Tetra-primer amplification refractory mutation system-polymerase chain (ARMS-PCR) is a simple and economical method for SNP determination. This method uses four primers, two outer primers, and two inner primers, followed by conventional PCR and gel electrophoresis. When conditions are optimal, this method has good accuracy and efficiency in detecting SNPs [14].

CYP3A5*3 allele variations are found in the American (80%) and European (94%) racial populations, while in the ASEAN population 65.7% with variations in the Thai population 37.7%; Vietnam 43.05%, Singapore 57.38% [15]. Based on the literature review conducted by the researchers, no study has been conducted on the variation of *CYP3A5*3* gene in the Indonesian-Javanese population, while for *CYP3A4,* the frequency of polymorphism of the gene in the Javanese population was found as follows: *CYP3A4*1/*1* 0.25; *CYP3A4*1/*1G* 0.55; and *CYP3A4*1G/*1G* 0.20 detected using the RFLP method [16]. This article reports *CYP3A5*3* and *CP3A4*1G* polymorphisms in the Indonesian-Javanese population using ARMs-PCR tetra primer method to detect *CYP3A4*1G rs2242480* and *CYP3A5*3 rs776746.*

Material and Methods
Subjects

Patients from Kalasan Community Health Centre, Yogyakarta, Indonesia, who met the inclusion criteria > 14 years, were of Indonesian-Javanese descent (subjects were surveyed for ethnicity background of three generations ago) and consented to blood collection by signing an informed consent form. The subjects were patients in the Amlodipine Efficacy and Side Effects Study. This study was conducted with ethical approval from the Medical and Health Research Ethics Committee of the Faculty of Medicine, Public Health and Nursing, Gadjah Mada College, under the number KE/FK/0871/ EC /2022.

DNA isolation

A total of 86 peripheral blood samples from patients of Kalasan Community Health Centre, Yogyakarta, Indonesia, were isolated using Favor-Prep Blood Genomic DNA Extraction Mini Kit. DNA isolation was performed according to the instructions on the kit. DNA concentration was measured using a Nanodrop spectrophotometer (TECAN SPARK 20M). Analysis of the quality of the DNA isolates using 1.0% agarose gel and electrophoresis (Sigma-Aldrich®).

Primer design

The *CYP3A4*1G* (rs2242480) variant is located at position chr7:99763843 and has a base C to T change, whereas *CYP3A5*3* (rs776746) is located at position chr7:99672916 with a base T to C change (https://www.ncbi.nlm.nih.gov). The DNA sequences of *CYP3A4*1G* and *CYP3A5*3* were obtained from a database search in NCBI and then used as a reference for primer design (Figures 1 and 2). Two pairs of different primers were designed using Geneious software, consisting of outer forward primers and inner reverse primers to detect single nucleotide polymorphism (SNP), as well as inner forward primers and outer reverse primers that have the function of detecting wild type. Illustrations of the primer design are provided in Figures 1 and 2. The results of the primer design are shown in Table 1 for *CYP3A4*1G* and in Table 2 for *CYP3A5*3*. The specificity of the outer primers in detecting *CYP3A4*1G* and *CYP3A5*3* was tested using the program NCBI BLAST (http://www.ncbi.nlm.nih.gov/blast).

Identification of CYP3A4*1G SNP using the tetra-primer ARMS PCR method

The identification of *CYP3A4*1G* SNP was performed in several steps, namely optimization of the tetra-primer ARMS PCR by determining the

a

b

Figure 1. (a) Location of primer designs used in the Tetra-Primer ARMS PCR. T and C symbolize the change from cytosine to thymine. The DNA sequence used as a reference for the primer design is from the genomic scaffold of Homo sapiens chromosome 7, GRCh38.p14 with |ref|NC_000007.14| (https://www.ncbi.nlm.nih.gov/projects/sviewer/?id=NC_000007.14&v=99763843:99763843&mk=9-9763843|rs2242480|008000). The flanking region of rs2242480 is from NCBI https://www.ncbi.nlm.nih.gov/snp/rs2242480#flanks (b) Illustration of the identification results of CYP3A4*1G (rs2242480) by agarose gel electrophoresis.

Table 1. Primers used in the tetra-primer ARMS PCR for detection of CYP3A4*1G polymorphism.

Primer set and sequences	‡Tm (°C)	hairpin	Product size
forward outer primer: 5' ATGTGAAATGAG-TGTGAGC 3'	53.3	None	321 bp‡
Reverse inner primer: 5' CAATAAGGTGAGTG-GATGA 3'	51.5	None	
Forward inner primer: 5' CCCTCCTTCTCCATGTAC 3'	53.2	None	215 bp‡
Reverse outer primer: 5' TCTTTCCTCTCCTTTCAGC 3'	54.1	None	

Noted: ‡Tm: Melting Temperature; bp: base pair

optimal annealing temperature and subsequent amplification with primers designed with a touch-down PCR system to avoid smear and prevent mis-priming [17]. The PCR kit used was the PowerPol 2x PCR Mix, which consists of DNA polymerase, dNTPs, MGCl2, KCl, and other stabilizers mixed with outer and inner primers. The primer concentration used in this analysis was 40 pmol/microliter. In one PCR tube contained five microliters of DNA isolate, four primers with a volume of 1 microliter each, 12.5 microliters of Taq polymerase, and 3.5 microliters of nuclease-free water. Amplification was performed using a PCR instrument (Perkin Elmer thermal cycler

Figure 2. (a) DNA sequence used as a reference for primer design, taken from the genomic scaffold of Homo sapiens chromosome 7, GRCh38.p14 with |ref|NC_000007.14|(https://www.ncbi.nlm.nih.gov/projects/sviewer/?id=NC_000007.14&v=99672916:99672916&mk=99672916|rs776746|008000). The flanking region rs776746 was obtained from NCBI https://www.ncbi.nlm.nih.gov/snp/rs776746-#flanks . (b) Representation of the identification results of CYP3A5*3 rs776746 by agarose gel electrophoresis.

Table 2.   Primers used in the tetra-primer ARMS PCR for detection of CYP3A5*3 polymorphisms.

Primer set and sequences	‡Tm (°C)	hairpin	Product size
forward outer primer: 5' CTAGCAC-TGTTCTGATCAC 3'	52.8	None	318 bp‡
Reverse inner primer: 5' GAGCTCTTTT-GTCTTTCAG 3'	51.4	None	
Forward inner primer: 5' CCAAACAGGGAAGA-GATAT 3'	51.1	None	208 bp‡
Reverse outer primer: 5' CACTTGATGATTTAC-CTGC 3'	51.5	None	

2400). The PCR conditions used are listed in Table 3.

All PCR products are quantitatively tested using 1.5% agarose gel electrophoresis and compared with the 50 bp DNA ladder (ExcelBand™). Electrophoresis results were performed at 110 volts for 30 minutes. Electrophoresis results were viewed with a UV transilluminator lamp and documented with a DSLR camera.

Identification of CYP3A5*3 SNPs by the tetra-primer method ARMS PCR

The identification of CYP3A5*3 SNPs was performed in several steps, namely the optimization of the tetra-primer ARMS PCR by determining the optimal annealing temperature. The PCR kit used is the PowerPol 2x PCR Mix, which consists of DNA polymerase, dNTPs, MGCl2, KCl, and other stabilizers mixed with outer and inner

primers. Primer concentrations used in this analysis were five pmol/microliter for outer forward and reverse primers and 30 pmol/microliter for inner forward and reverse primers. The choice of primer concentration is determined by the concentration optimization method using primer comparison referring to previous research [18,19]. In one PCR tube, five microliters of DNA isolate were mixed with four primers (1 microliter each), Taq polymerase (12.5 microliters), nuclease-free water (3.5 microliters), and PCR was performed with a temperature setting of pre-denaturation at 98°C for 45 seconds, denaturation at 98°C for 10 seconds, annealing at 56.90°C for 15 seconds, elongation at 72°C for 30 seconds, and final elongation at 72°C for 5 minutes with 35 cycles. PCR products were quantitatively tested by gel electrophoresis.

Statistical calculations

Deviations of genotypes from Hardy-Weinberg equilibrium were calculated by chi-square test with a significance level of 0.05 using Hardy-Weinberg Equilibrium Gene-Calc. Differences in genotype distribution between sexes were analysed by chi-square test with statistically significant differences at a P value < 0.05.

Results and Discussion

ARMS PCR method for each single nucleotide polymorphism (SNP) is shown in Figures 3 and 4. Figure 3 shows that samples with *CYP3A4*1/*1G* variations formed 321 bp and 215 bp products (a, b), whereas *CYP3A4*1/*1* variations formed 215 bp products (c). Product 321 bp (d) for *CYP3A4*1G/*1G* variation. The *CYP3A5*3/*3* SNP variation is indicated by the presence of a 318 bp product (a, b, d, f), and *CYP3A5*1/*3* formed 318 bp and 208 bp products (c, g, e).

The genotype and allele frequencies of *CYP3A4*1G* and *CYP3A5*3* polymorphisms in the Indonesian-Javanese population are shown in Tables 4 and 5. The results of this study show that genotype frequencies are consistent with Hardy-Weinberg equilibrium (p>0.005). Homozygous wild types *CYP3A4*1/*1* dominated in the study participants overall (73.35%), while for *CYP3A5*3/*3*, homozygous mutants had the highest number (83.72%), and homozygous wild types were not found in the same group of subjects. The combined variation of SNPs in both genes within a subject is shown in Table 6. Forty-nine subjects were heterozygous for *CYP3A4*1G* and

homozygous mutant for *CYP3A5*3*, and only one subject had a homozygous mutation for *CYP3A4*1G* and *CYP3A5*3*. Chi-square analysis showed no difference in the distribution of the number of genotypes between the sexes (Table 4).

In this study, the frequency of the *CYP3A4*1/*1* genotype was higher (73.25%) than in the study by Sutrisna *et al.*, [16] who investigated the same SNP in the Indonesian population but specifically in Javanese tribes. In addition, the genotypes of *CYP3A4*1/*1G* and *CYP3A4*1G/*1G* were lower in this study than in the study by Sutrisna *et al.* [16]. However, this study and Sutrina's research showed that the genotype frequency was still in Hardy-Weinberg equilibrium. Sutrisna's research used the RFLP method, which is different from the detection strategy employed in this study. The RFLP approach is costly and has the potential to result in incomplete and/or partial digestion, leading to false negative or positive [13].

The allele frequency in this study showed 86% for *1 and 14% for *1G. In other Asian populations, the allele frequency of *1G is slightly higher than the Indonesian-Javanese population, 24.01% for Chinese-Han, 22.80% for Japanese, and 20.5% for Korean. However, the number is almost the same as Chinese-Uyghur (11.5%) [20]. It is well known that the presence of the *CYP3A4*1G* allele causes changes in the pharmacokinetic profile of some drugs. For example, a study by Zhou et al [7]. showed that the concentrations of diltiazem and its primary metabolites were strongly influenced by the *CYP3A4*1G* allele [7]. The average area under the plasma concentration-time curve of atorvastatin was 36% and 25% lower in *CYP3A4*1G/*1* than in the wild-type or *1/*1G genotype, respectively [21]. In other cases, the *CYP3A4*1G* polymorphism significantly affects the pharmacokinetics of ticagrelor [22].

CYP3A4*1G and *CYP3A5*3* are known to have strong linkage disequilibrium. No linkage disequilibrium studies were performed for these two variations in this study. The researchers calculated the linkage disequilibrium between the two alleles using LDlink (https://analysistools.cancer.gov/LDlink/?tab=ldpair) by selecting the entire Asian population (East and South Asia) and obtained r2 = 0.5714, indicating a moderate level of linkage disequilibrium. In addition to the calculation results, it was discovered that the *rs2242480* (C) allele was correlated with the

Figure 3. Gel electrophoresis results of *CYP3A4*1G* polymorphism detection using Tetra-primer ARMS PCR. (a), (b) show heterozygotes with the appearance of 2 bands at 321 bp and 215 bp. (c) shows homozygous wild type with the occurrence of 1 band at 215 bp. (d) shows homozygous mutant with the occurrence of 1 band at 321 bp.


Figure 4. Gel electrophoresis results of *CYP3A5*3* polymorphism detection using Tetra- primer ARMS PCR. (a), (b), (d), (f) show the homozygous mutant with the appearance of 1 band at 318 bp. (c), (e), (g) shows the heterozygous with the occurrence of 2 bands at 318 bp and 208 bp.

Table 4. Gene characteristics by sex

genotipe	*CYP3A4*1/*1*	*CYP3A4*1/*1G*	*CYP3A4*1G/*1G*	p*
Sex	(n)	(n)	(n)	
Male	7	25	0	0.597
Female	15	38	1	
genotipe	*CYP3A5*1/*1*	*CYP3A5*1/ *3*	*CYP3A4*3/*3*	
Sex	(n)	(n)	(n)	
Male	0	8	46	0,633
Female	0	6	26	

*Chi-square test (p < 0.05)

rs776746 (C) allele, and the *rs 2242480* (T) allele was also found to be correlated with the *rs776746* (T) allele. The study by Zhou et al [7]. showed a strong linkage disequilibrium between *CYP3A4*1G* and *CYP3A5*3* in the Chinese population. However, another study demonstrated a moderate level of LD between *CYP3A4*1/*1G* and *CYP3A5*1/*3* (r^2 = 0.502) [23]. The presence of linkage disequilibrium is a challenge in the study of drug metabolism. The primary reason is because the explanation of the activity of the drug-metabolizing enzyme in individuals is influenced not only by one gene locus but also by other alleles located at different sites on the same chromosome.

Table 5. Genotype and allele frequencies in test subjects

subject	Genotype frequency	Allele frequency	Hardy-Weinberg equilibrium
CYP3A4			
- *CYP3A4 *1/*1*	63 (73.25%)		The χ^2 value obtained is 0.361. This value is smaller than the chi-square value of 3.841.
- *CYP3A4 *1/*1G*	22 (25.58%)		
- *CYP3A4 *1G/*1G*	1 (1.16 %)		
- Allele C (*1)		0.86	
- Allele T (*1G)		0.14	
CYP3A5			The χ^2 value obtained is 0.684. This value is smaller than the chi-square value of 3.841.
- *CYP3A5 *1/*1*	0 (0 %)		
- *CYP3A5 *1/*3*	14 (16.27 %)		
- *CYP3A5 *3/*3*	72 (83.72 %)		
- Allele T (*1)		0.08	
- Allele C (*3)		0.92	

‡ C: Cytosine; T: Timine

Table 6. Genotype frequencies of *CYP3A4*1G* and *CYP3A5*3* polymorphisms in the same individual

Combinations of genotypes in one individual	Total
*CYP3A4*1/*1* and *CYP3A5*3/*3*	22 (25.58%)
*CYP3A4*1/*1G* and *CYP3A5*1/*3*	14 (16.28%)
*CYP3A4*1/*1G* and *CYP3A5*3/*3*	49 (56.98%)
*CYP3A4*1G/*1G* and *CYP3A5 *3/*3*	1 (1.16%)

The study by Chan et al [24], for example, showed that *CYP3A5* expressors (patients carrying at least one *CYP3A5*1*) with a combination of *CYP3A4*1/*1G* had a significantly lower midazolam AUC than those who carry *CYP3A4*1/*1*. This suggests that the linkage disequilibrium between *CYP3A5*1* and *CYP3A4*1G* affects the action of metabolizing enzymes, whereby the *CYP3A4*1G* polymorphism may increase CYP3A activity in populations with *CYP3A5* expressors.

This study identified that the most prevalent variant of the *CYP3A5* gene was *CYP3A5*3/*3* (83.72%) with a C allele frequency of 0.92. *CYP3A5*3/*3* is also the most prevalent genotype in several other Asian populations, including China (54.90%), Japan (58.40%), Korea (62.85%), and Taiwan (47.25%). However, compared to the population of Singapore of Malaysian and Indian descent, the percentage of *CYP3A5*1/*3* is higher, at 50% and 46.46%, respectively [15]. Carriers of the *CYP3A5*3* gene are more likely to develop clopidogrel resistance [25]. In another study, *CYP3A5* expressors (*1/*1

and *1/*3) correlated positively with carbamazepine serum concentrations and carbamazepine dose requirements [26]. The *CYP3A5* genotype also influences oral clearance of nifedipine in pregnant women [27]. This study also demonstrated that the distribution of each genotype did not differ significantly between genders. This result was also observed in studies with more participants [28].

This study is limited by the small sample size, but it does provide an overview of the *CYP3A4*1G* and *CYP3A5*3* genotype variations in the Indonesian-Javanese population. In conclusion, the incidence of *CYP3A4*1G* in the Indonesian-Javanese population was 73.25% for *CYP3A4*1/*1*, 25.58% for *CYP3A4*1/*1G*, and 1.16% for *CYP3A4 *1G/*1G*. Meanwhile, the variance of *CYP3A5*3* genotypes was 16.27% for *CYP3A5 *1/*3* and 83.72% for *CYP3A5*3/*3*.

Conclusion

The results of the current study show that the population has the highest proportion of homozy

gous *CYP3A4*1G* wild type and homozygous mutants of *CYP3A5*3*. One subject had a homozygous mutation for both *CYP3A4*1G* and *CYP3A5*3*, while the other 49 subjects were heterozygous for *CYP3A4*1G* and homozygous mutant for *CYP3A5*3*. Chi-square analysis showed no difference in the distribution of the number of genotypes between the sexes.

Acknowledgment

References

1. Zuo XC, Zhou YN, Zhang BK et al. (2013) Effect of CYP3A5*3 polymorphism on Pharmacokinetic drug interaction between tacrolimus and amlodipine. Drug Metabolism and Pharmacokinetics 28 (5): 398–405. doi: 10.2133/dmpk.DMPK-12-RG-148.
2. Tornio A, Backman JT (2018) Cytochrome P450 in Pharmacogenetics: An Update, 1st ed. Adv Pharmacol. doi: 10.1016/bs.apha.2018.04.007
3. Saiz-Rodríguez M, Almenara S, Navares-Gómez M et al. (2020) Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines. doi: 10.3390/biomedicines8040094
4. Lamba J, Hebert JM, Schietz EG et al. (2016) PharmGKB summary: Very important pharmacogene information for MT-RNR1. Pharmacogenetics and Genomics 26 (12): 558–567. doi: 10.1097/FPC.0000000000000247.
5. Zhang W, Chang YZ, Kan QC et al. (2010) CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. European Journal of Clinical Pharmacology 66 (1): 61–66. doi: 10.1007/s00228-009-0726-4.
6. Zuo XC, Ng CM, Barrett JS et al. (2013) Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: A population pharmacokinetic analysis. Pharmacogenetics and Genomics 23 (5): 251–261. doi: 10.1097/FPC.0b013e32835fcbb6.
7. Zhou LY, Zuo XC, Chen K et al. (2016) Significant impacts of CYP3A4*1G and CYP3A5∗3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. Journal of Clinical Pharmacy and Therapeutics 41 (3): 341–347. doi: 10.1111/jcpt.12394.
8. Zhang H, Chen M, Wang X, Yu S (2017) Patients with CYP3A4∗1G genetic polymorphism consumed significantly lower amount of sufentanil in general anesthesia during lung resection. Medicine (United States) 96 (4): 2016–2018. doi: 10.1097/MD.0000000000006013.
9. Zhou S, Tao M, Wang Y et al. (2019) Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects. Xenobiotica 49 (3): 375–380. doi:
10. Liu X, Huang X, Zhang S et al. (2019) Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population. International Journal of Clinical Oncology 24 (2): 179–188. doi: 10.1007/s10147-018-1346-8.
11. Kitzmiller JP, Luzum JA, Baldassarre D et al. (2014) CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort. Pharmacogenetics and Genomics 24 (10): 486–491. doi: 10.1097/FPC.0000000000000079.
12. Durand P, Debray D, Kolaci M et al. (2013) Tacrolimus dose requirement in pediatric liver transplantation: Influence of CYP3A5 gene polymorphism. Pharmacogenomics 14 (9): 1017–1025. doi: 10.2217/pgs.13.87.
13. Honardoost MA, Tabatabaeian H, Akbari M, Salehi M (2014) Investigation of sensitivity, specificity and accuracy of Tetra primer ARMS PCR method in comparison with conventional ARMS PCR, based on sequencing technique outcomes in IVS-II-I genotyping of beta thalassemia patients. Gene 549 (1): 1–6. doi: 10.1016/j.gene.2014.05.071.
14. Medrano RFV, De Oliveira CA (2014) Guidelines for the tetra-primer ARMS-PCR technique development. Molecular Biotechnology 56 (7): 599–608. doi: 10.1007/s12033-014-9734-4.
15. Dorji PW, Tshering G, Na-Bangchang K (2019) CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review. Journal of Clinical Pharmacy and Therapeutics 44 (4): 508–524. doi: 10.1111/jcpt.12835.
16. Sutrisna E, Dwiprahasto I (2011) CYP3A4* 1G gene Polymorphism on Javanese People. Indonesian Journal of Biotechnology 16 (2): 83–87. doi: https://doi.org/10.22146/ijbiotech.16373.
17. Korbie DJ, Mattick JS (2008) Touchdown PCR for increased specificity and sensitivity in PCR amplification. Nature Protocols 3 (9): 1452–1456. doi: 10.1038/nprot.2008.133.
18. Suhda S, Paramita DK, Fachiroh J (2016) Tetra primer ARMS PCR optimization to detect single nucleotide polymorphisms of the CYP2E1 gene. Asian Pacific Journal of Cancer Prevention 17 (7): 3065–3069. doi: 10.14456/apjcp.2016.54/APJCP.2016.17.7.3065.
19. Dewi AL, Paramita DK, Fachiroh J (2022) Tetra-primer amplification refractory mutation system (ARMS) PCR used to detect 3'UTR rs1948 mutation in CHRNB4. Indonesian Journal of Biotechnology 27 (1): 1–7. doi: 10.22146/ijbiotech.64933.
20. Hu GX, Dai DP, Wang H et al. (2017) Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population. Pharmacogenomics 18 (4): 369–379. doi: 10.2217/pgs-2016-0179.
21. He BX, Shi L, Qiu J et al. (2014) The effect of CYP3A41G allele on the pharmacokinetics of atorvastatin in Chinese han patients with coronary heart disease. Journal of Clinical Pharmacology 54 (4): 462–467. doi: 10.1002/jcph.229.
22. Liu S, Shi X, Tian X et al. (2017) Effect of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics and pharmacodynamics of ticagrelor in healthy chinese

subjects. Frontiers in Pharmacology 8 (176): 1–8. doi: 10.3389/fphar.2017.00176.

23. Li CJ, Li L, Lin L et al. (2014) Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. PLoS ONE 9 (1): 1–9. doi: 10.1371/journal.pone.0086206.

24. Chan SW, Xiao Y, Hu M et al. (2016) Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. Journal of Clinical Pharmacy and Therapeutics 41 (5): 552–558. doi: 10.1111/jcpt.12433.

25. Priyadharsini R, Shewade DG, Subraja K et al. (2014) Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population. Molecular Biology Reports 41 (11): 7265–7271. doi: 10.1007/s11033-014-3613-8.

26. Hong PT, Minh HHT, Thi VH, Manh3 TH (2020) Effect of CYP3A5 genotypes on serum carbamazepine concentrations at steady-state in Vietnamese epileptic patients. Res J Pharm Technol. doi: 10.5958/0974-360X.2020.00498.9

27. M D, Quinney KS, Clay MJ et al. (2014) Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. Exp Biol Med 30 (11): 271–281. doi: 10.1055/s-0032-1323590.

28. Maurya MR, Gautam S, Raj JP et al. (2022) Evaluation of genetic polymorphism of CYP3A5 in normal healthy participants from western India - A cross-sectional study. Indian Journal of Pharmacology 54 (2): 97–101. doi: 10.4103/ijp.ijp_279_21.

This page is intentionally left blank.

The Genetic Polymorphisms of CYP3A4*1G and CYP3A5*3 in Javanese Indonesian Population

| 5 | www2.mdpi.com
Internet Source | 1% |

| 6 | pure.uva.nl
Internet Source | 1% |

| 7 | garuda.ristekbrin.go.id
Internet Source | 1% |

| 8 | Seung-Cheol Goh, Chung-Nim Lee. "Counting minimal 18-paths in 3D digital space", Pattern Recognition Letters, 1993
Publication | 1% |

| 9 | d.docksci.com
Internet Source | 1% |

| 10 | export.arxiv.org
Internet Source | 1% |

| 11 | Wei Zhang, Jing-Jing Yuan, Quan-Cheng Kan, Li-Rong Zhang, Yan-Zi Chang, Zhong-Yu Wang, Zhi-Song Li. "Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery", European Journal of Anaesthesiology, 2011
Publication | 1% |

| 12 | biomedres.us
Internet Source | 1% |

13 Alison E. Fohner, Rachel Dalton, Kasse Skagen, Konner Jackson et al. " Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting allele function ", Clinical and Translational Science, 2021
Publication

<1 %

14 baerjournal.org
Internet Source

<1 %

15 Guy-Viterbo, Vanessa, Henry Baudet, Laure Elens, Vincent Haufroid, Florence Lacaille, Muriel Girard, Dominique Debray, Christophe Chardot, Raymond Reding, Pierre Wallemacq, and Flora Musuamba. "Influence of donor–recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach", Pharmacogenomics, 2014.
Publication

<1 %

16 ojs.ksu.edu.kz
Internet Source

<1 %

17 Michael J Frank. "Prefrontal and striatal dopaminergic genes predict individual differences in exploration and exploitation", Nature Neuroscience, 08/2009
Publication

<1 %

18 Qian Zhu, Wanping Zhong, Xipei Wang, Liping Mai, Guodong He, Jiyan Chen, Lan Tang, Shuwen Liu, Weihua Lai, Shilong Zhong. "Pharmacokinetic and Pharmacogenetic Factors Contributing to Platelet Function Recovery After Single Dose of Ticagrelor in Healthy Subjects", Frontiers in Pharmacology, 2019
Publication   <1 %

19 www.omicsdi.org
Internet Source   <1 %

20 Li, Chuan-Jiang, Liang Li, Li Lin, Hai-Xia Jiang, Ze-Yan Zhong, Wei-Mo Li, Yan-Jun Zhang, Ping Zheng, Xu-Hui Tan, and Lin Zhou. "Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR Genetic Polymorphisms on Tacrolimus Metabolism in Chinese Renal Transplant Recipients", PLoS ONE, 2014.
Publication   <1 %

21 Bao-xia He, Lei Shi, Jian Qiu, Xiao-Hui Zeng, Shu-Jin Zhao. "The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese han patients with coronary heart disease", The Journal of Clinical Pharmacology, 2014
Publication   <1 %

22 Chunying Zhang, Qiyuan Zheng, Fengting Pan, Ting Wang, Yalin Zhao, Zhaoguang Xiao,   <1 %

Zehan Huang. " Significance of CYP3A4 1G and OPRM1 A118G Polymorphisms in Postoperative Sufentanil Analgesia in Women of Different Ethnicities ", Computational and Mathematical Methods in Medicine, 2022
Publication

23 David Haas, Sara Quinney, Jayanti Clay, Jamie Renbarger, Mary Hebert, Shannon Clark, Jason Umans, Steve Caritis. "Nifedipine Pharmacokinetics Are Influenced by CYP3A5 Genotype When Used as a Preterm Labor Tocolytic", American Journal of Perinatology, 2012
Publication

<1 %

24 bmcplantbiol.biomedcentral.com
Internet Source

<1 %

25 Emilia Vivi Arsita, Dwi Aris Agung Nugrahaningsih, Ahmad Hamim Sadewa. "GSTM1 Deletion Compensated in mRNA Expression and 4T1 Viability After Editing Using CRISPR/Cas9 Single and Double gRNA", The Indonesian Biomedical Journal, 2023
Publication

<1 %

26 Suhui Wu, Shi Lu, Huijuan Tao, Li Zhang, Weifeng Lin, Haixia Shang, Jun Xie. "Correlation of polymorphism of IL-8 and MMP-7 with occurrence and lymph node metastasis of early stage cervical cancer",

<1 %

Journal of Huazhong University of Science
and Technology [Medical Sciences], 2011
Publication

27   Submitted to University of Hong Kong   <1%
      Student Paper

28   ijmaberjournal.org   <1%
      Internet Source

29   irjournal.org   <1%
      Internet Source

30   rdcb.cbg.ipn.mx   <1%
      Internet Source

31   www.biorxiv.org   <1%
      Internet Source

32   John S Mattick. "Touchdown PCR for   <1%
      increased specificity and sensitivity in PCR
      amplification", Nature Protocols, 08/2008
      Publication

33   Junbo Tian, Jing Zhang, Zengguang Yang,   <1%
      Shuaisheng Feng et al. "Genetic Epidemiology
      of Medication Safety and Efficacy Related
      Variants in the Central Han Chinese
      Population With Whole Genome Sequencing",
      Frontiers in Pharmacology, 2022
      Publication

34   Submitted to Leiden University   <1%
      Student Paper

35 biblio.ugent.be
Internet Source   <1%

36 brenda-enzymes.org
Internet Source   <1%

37 etheses.whiterose.ac.uk
Internet Source   <1%

38 Kang Xiao, Jie Gao, Shi-Jia Weng, Yan Fang, Na
Gao, Qiang Wen, Han Jin, Hai-Ling Qiao.
"CYP3A4/5 Activity Probed with Testosterone
and Midazolam: Correlation between Two
Substrates at the Microsomal and Enzyme
Levels", Molecular Pharmaceutics, 2018   <1%
Publication

39 Lolita Lolita, Ming Zheng, Xiang Zhang, Zhijian
Han et al. "The Genetic Polymorphism of
CYP3A4 rs2242480 is Associated with
Sirolimus Trough Concentrations Among
Adult Renal Transplant Recipients", Current   <1%
Drug Metabolism, 2020
Publication

40 Mahrukh Nasir, Muhammad Nauman Khan,
Najia Aslam Soomro, Khalid Naseeb et al.
"Analysis of genetic mutation in dilated   <1%
cardiomyopathy", Gene Reports, 2023
Publication

41 S. W. Chan, Y. Xiao, M. Hu, O. Q. P. Yin, T. T.
W. Chu, B. S. P. Fok, V. H. L. Lee, B. Tomlinson. <1%

" Associations of the and * polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese ", Journal of Clinical Pharmacy and Therapeutics, 2016
Publication

42	journals.plos.org Internet Source	<1 %
43	jppres.com Internet Source	<1 %
44	m.moam.info Internet Source	<1 %
45	manualzz.com Internet Source	<1 %
46	ptj.uswr.ac.ir Internet Source	<1 %
47	stax.strath.ac.uk Internet Source	<1 %
48	www.jstage.jst.go.jp Internet Source	<1 %
49	www.mdpi.com Internet Source	<1 %
50	www.xyeyy.com Internet Source	<1 %

51	zbw.eu Internet Source	<1 %
52	"Abstracts", Pharmacoepidemiology and Drug Safety, 2012. Publication	<1 %

Exclude quotes	Off	Exclude matches	Off
Exclude bibliography	On		